BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36514045)

  • 1. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure.
    Qu R; Kluger Y; Yang J; Zhao J; Hafler DA; Krause DS; Bersenev A; Bosenberg M; Hurwitz M; Lucca L; Kluger HM
    Mol Cancer; 2022 Dec; 21(1):219. PubMed ID: 36514045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy.
    Lu YC; Jia L; Zheng Z; Tran E; Robbins PF; Rosenberg SA
    Cancer Immunol Res; 2019 Nov; 7(11):1824-1836. PubMed ID: 31484655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
    Zhou J; Dudley ME; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
    Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
    Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
    Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cells Expanded from PD-1
    Li T; Zhao L; Yang Y; Wang Y; Zhang Y; Guo J; Chen G; Qin P; Xu B; Ma B; Zhang F; Shang Y; Li Q; Zhang K; Yuan D; Feng C; Ma Y; Liu Z; Tian Z; Li H; Wang S; Gao Q
    Cancer Res; 2021 Apr; 81(8):2184-2194. PubMed ID: 33408117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
    Huang J; Khong HT; Dudley ME; El-Gamil M; Li YF; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(3):258-67. PubMed ID: 15838383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
    Diaz-Cano I; Paz-Ares L; Otano I
    Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
    Zhou J; Shen X; Huang J; Hodes RJ; Rosenberg SA; Robbins PF
    J Immunol; 2005 Nov; 175(10):7046-52. PubMed ID: 16272366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human autologous tumor-specific T cells in malignant melanoma.
    Platsoucas CD
    Cancer Metastasis Rev; 1991 Jun; 10(2):151-76. PubMed ID: 1873855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.